Objective To explore the characteristics of tumor related anemia in patients with NSCLC before and after chemotherapy. Methods Clinical data of 122 patients with NSCLC from January 2014 to December 2015 were collected.Statistical line 4 cycles, 6 cycles of chemotherapy before and during chemotherapy, and during the review period HbG value, HbG value of combined therapy of iron complex, folic acid and vitamin B12 in the treatment of anemia patients before and after treatment. Data analysis using SPSS19.0 software.Results Before the start of chemotherapy, the value of HbG was higher than that of HbG after chemotherapy. Comparison of HbG value two two after two cycles of chemotherapy before and after chemotherapy, there were statistically significant differences in HbG values between first cycles and second cycles (P=0.003) chemotherapy in patients with only 4 cycles of chemotherapy, there were no significant statistical differences (>0.05 mean P). 4 cycles of chemotherapy for patients with the first cycle of chemotherapy before and after the last chemotherapy and delta of HbG Chinese value compared with six cycles of chemotherapy in patients with no significant difference (t=0.922, P=0.359). There were 5 patients with 4 cycles of chemotherapy, 6 patients with cycles of chemotherapy and 8 patients with HbG were higher than first cycles before chemotherapy. 3 HbG values were reviewed, the difference was not statistically significant (F-measure was 2.011,2.996; P value was 0.136,0.053). During the chemotherapy of oral triple drug corrected 7 cases of anemia, before and after treatment HbG values compared with the untreated patients there is significant difference. 5 cases of chemotherapy after medication, the HbG values showed no significant difference compared with untreated patients. Conclusion Chemotherapy can lead to a decrease in HbG values in patients with NSCLC. 4 cycles of chemotherapy and 6 cycles of chemotherapy to patients with the same HbG value decreased. Du |
